Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Current Assets (2020 - 2025)

Historic Current Assets for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $97.2 million.

  • Pulse Biosciences' Current Assets rose 2082.1% to $97.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.2 million, marking a year-over-year increase of 2082.1%. This contributed to the annual value of $119.4 million for FY2024, which is 16352.14% up from last year.
  • According to the latest figures from Q3 2025, Pulse Biosciences' Current Assets is $97.2 million, which was up 2082.1% from $108.2 million recorded in Q2 2025.
  • Pulse Biosciences' 5-year Current Assets high stood at $120.9 million for Q1 2025, and its period low was $22.2 million during Q1 2022.
  • Over the past 5 years, Pulse Biosciences' median Current Assets value was $60.0 million (recorded in 2023), while the average stood at $63.1 million.
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 6423.94% in 2022, then surged by 29707.77% in 2025.
  • Quarter analysis of 5 years shows Pulse Biosciences' Current Assets stood at $45.3 million in 2021, then surged by 37.11% to $62.1 million in 2022, then fell by 27.06% to $45.3 million in 2023, then soared by 163.52% to $119.4 million in 2024, then dropped by 18.66% to $97.2 million in 2025.
  • Its Current Assets stands at $97.2 million for Q3 2025, versus $108.2 million for Q2 2025 and $120.9 million for Q1 2025.